Anavex Life Sciences (AVXL) Competitors $8.63 +0.16 (+1.89%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AVXL vs. XENE, MRUS, ACAD, TWST, VCEL, MOR, KYMR, SWTX, ZLAB, and VERAShould you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include Xenon Pharmaceuticals (XENE), Merus (MRUS), ACADIA Pharmaceuticals (ACAD), Twist Bioscience (TWST), Vericel (VCEL), MorphoSys (MOR), Kymera Therapeutics (KYMR), SpringWorks Therapeutics (SWTX), Zai Lab (ZLAB), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry. Anavex Life Sciences vs. Xenon Pharmaceuticals Merus ACADIA Pharmaceuticals Twist Bioscience Vericel MorphoSys Kymera Therapeutics SpringWorks Therapeutics Zai Lab Vera Therapeutics Xenon Pharmaceuticals (NASDAQ:XENE) and Anavex Life Sciences (NASDAQ:AVXL) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, community ranking, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment. Does the media refer more to XENE or AVXL? In the previous week, Xenon Pharmaceuticals had 2 more articles in the media than Anavex Life Sciences. MarketBeat recorded 5 mentions for Xenon Pharmaceuticals and 3 mentions for Anavex Life Sciences. Xenon Pharmaceuticals' average media sentiment score of 0.80 beat Anavex Life Sciences' score of 0.66 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anavex Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in XENE or AVXL? 95.4% of Xenon Pharmaceuticals shares are held by institutional investors. Comparatively, 31.5% of Anavex Life Sciences shares are held by institutional investors. 5.5% of Xenon Pharmaceuticals shares are held by insiders. Comparatively, 11.0% of Anavex Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is XENE or AVXL more profitable? Xenon Pharmaceuticals' return on equity of -24.69% beat Anavex Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Xenon PharmaceuticalsN/A -24.69% -23.68% Anavex Life Sciences N/A -30.64%-28.23% Which has stronger earnings & valuation, XENE or AVXL? Anavex Life Sciences has lower revenue, but higher earnings than Xenon Pharmaceuticals. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXenon Pharmaceuticals$9.43M312.32-$182.39M-$2.82-13.70Anavex Life SciencesN/AN/A-$47.51M-$0.50-17.26 Do analysts rate XENE or AVXL? Xenon Pharmaceuticals currently has a consensus target price of $56.00, suggesting a potential upside of 44.97%. Anavex Life Sciences has a consensus target price of $43.00, suggesting a potential upside of 398.26%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Anavex Life Sciences is more favorable than Xenon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Anavex Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has more risk and volatility, XENE or AVXL? Xenon Pharmaceuticals has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Does the MarketBeat Community prefer XENE or AVXL? Anavex Life Sciences received 12 more outperform votes than Xenon Pharmaceuticals when rated by MarketBeat users. Likewise, 74.44% of users gave Anavex Life Sciences an outperform vote while only 69.95% of users gave Xenon Pharmaceuticals an outperform vote. CompanyUnderperformOutperformXenon PharmaceuticalsOutperform Votes41969.95% Underperform Votes18030.05% Anavex Life SciencesOutperform Votes43174.44% Underperform Votes14825.56% SummaryXenon Pharmaceuticals beats Anavex Life Sciences on 9 of the 16 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Anavex Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVXL vs. The Competition Export to ExcelMetricAnavex Life SciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$731.79M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E Ratio-17.2646.7390.0517.18Price / SalesN/A415.011,117.00116.99Price / CashN/A182.1042.9637.86Price / Book4.993.894.784.78Net Income-$47.51M-$42.21M$120.31M$225.60M7 Day Performance2.01%-2.15%-1.92%-1.23%1 Month Performance-4.32%4.20%11.50%3.36%1 Year Performance-1.37%18.39%30.59%16.60% Anavex Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVXLAnavex Life Sciences3.3395 of 5 stars$8.63+1.9%$43.00+398.3%-2.5%$731.79MN/A-17.2640High Trading VolumeXENEXenon Pharmaceuticals2.7904 of 5 stars$41.15+2.7%$56.90+38.3%-5.8%$3.14B$9.43M-14.20251Insider TradeMRUSMerus2.7827 of 5 stars$42.84+0.0%$85.64+99.9%+61.7%$2.93B$43.95M-10.8437ACADACADIA Pharmaceuticals3.8468 of 5 stars$17.50+1.4%$25.60+46.3%-41.9%$2.91B$726.44M22.13510TWSTTwist Bioscience2.5561 of 5 stars$48.94+3.0%$51.90+6.0%+36.7%$2.91B$312.97M-13.19990VCELVericel1.4381 of 5 stars$58.15+1.2%$59.71+2.7%+66.0%$2.87B$226.84M957.83300Analyst ForecastMORMorphoSys0.127 of 5 stars$18.96+2.4%$14.33-24.4%N/A$2.86B$238.28M-5.45730News CoverageKYMRKymera Therapeutics2.27 of 5 stars$43.90+4.2%$53.88+22.7%+66.0%$2.84B$87.56M-18.00170SWTXSpringWorks Therapeutics2.0068 of 5 stars$38.21-0.2%$69.50+81.9%+11.3%$2.84B$5.45M-9.87305ZLABZai Lab1.7093 of 5 stars$26.05-1.1%$55.00+111.1%-7.4%$2.83B$355.75M-9.512,175VERAVera Therapeutics3.4812 of 5 stars$44.53+1.1%$59.22+33.0%+180.4%$2.82BN/A-16.8840Insider Trade Related Companies and Tools Related Companies XENE Alternatives MRUS Alternatives ACAD Alternatives TWST Alternatives VCEL Alternatives MOR Alternatives KYMR Alternatives SWTX Alternatives ZLAB Alternatives VERA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AVXL) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anavex Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anavex Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
